Mission Statement:

To improve the care and outcomes of kidney disease
patients worldwide through promoting coordination,
collaboration and integration of initiatives to develop
and implement clinical practice guidelines.

About Us | Contact Us | Our Supporters
 

KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)

References

Kidney International (2009) 76 S1-S2; doi:10.1038/ki.2009.188
  1. Eknoyan G, Lameire N, Barsoum R et al. The burden of kidney disease: improving global outcomes. Kidney Int 2004; 66: 1310-1314.
  2. Moe S, Drueke T, Cunningham J et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69: 1945-1953.
  3. Bucher HC, Guyatt GH, Cook DJ et al. Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group. JAMA 1999; 282: 771-778.
  4. Counsell C. Formulating questions and locating primary studies for inclusion in systematic reviews. Ann Intern Med 1997; 127: 380-387.
  5. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: S1-201.
  6. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. Am J Kidney Dis 2005; 46: S1-121.
  7. Palmer SC, Strippoli GF, McGregor DO. Interventions for preventing bone disease in kidney transplant recipients: a systematic review of randomized controlled trials. Am J Kidney Dis 2005; 45: 638-649.
  8. Palmer SC, McGregor DO, Macaskill P et al. Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med 2007; 147: 840-853.
  9. Mitterbauer C, Schwarz C, Haas M et al. Effects of bisphosphonates on bone loss in the first year after renal transplantation--a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 2006; 21: 2275-2281.
  10. Strippoli GF, Palmer S, Tong A et al. Meta-analysis of biochemical and patient-level effects of calcimimetic therapy. Am J Kidney Dis 2006; 47: 715-726.
  11. Burke SK, Dillon MA, Hemken DE et al. Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients. Adv Ren Replace Ther 2003; 10: 133-145.
  12. D'Haese PC, Spasovski GB, Sikole A et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int 2003; 63(Suppl 85): S73-78.
  13. Freemont AJ, Hoyland JA, Denton J. The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease. Clin Nephrol 2005; 64: 428-437.
  14. Atkins D, Best D, Briss PA et al. Grading quality of evidence and strength of recommendations. BMJ 2004; 328: 1490.
  15. Sterrett JR, Strom J, Stummvoll HK et al. Cinacalcet HCI (Sensipar/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol 2007; 68: 10-17.
  16. Fujii N, Hamano T, Mikami S et al. Risedronate, an effective treatment for glucocorticoid-induced bone loss in CKD patients with or without concomitant active vitamin D (PRIUS-CKD). Nephrol Dial Transplant 2007; 22: 1601-1607.
  17. Salusky IB, Goodman WG, Sahney S et al. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols. J Am Soc Nephrol 2005; 16: 2501-2508.
  18. Salusky IB, Kuizon BD, Belin TR et al. Intermittent calcitriol therapy in secondary hyperparathyroidism: a comparison between oral and intraperitoneal administration. Kidney Int 1998; 54: 907-914.
  19. Vimalachandra D, Hodson EM, Willis NS et al. Growth hormone for children with chronic kidney disease. Cochrane Database Syst Rev 2006; 3: CD003264.
  20. Parfitt AM. Renal bone disease: a new conceptual framework for the interpretation of bone histomorphometry. Curr Opin Nephrol Hypertens 2003; 12: 387-403.
  21. Freemont T, Malluche HH. Utilization of bone histomorphometry in renal osteodystrophy: demonstration of a new approach using data from a prospective study of lanthanum carbonate. Clin Nephrol 2005; 63: 138-145.
  22. Uhlig K, Macleod A, Craig J et al. Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 70: 2058-2065.
  23. Guyatt GH, Oxman AD, Kunz R et al. Going from evidence to recommendations. BMJ 2008; 336: 1049-1051.
  24. Guyatt GH, Oxman AD, Kunz R et al. What is 'quality of evidence' and why is it important to clinicians? BMJ 2008; 336: 995-998.
  25. AGREE Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care 2003; 12: 18-23.
  26. Shiffman RN, Shekelle P, Overhage JM et al. Standardized reporting of clinical practice guidelines: a proposal from the Conference on Guideline Standardization. Ann Intern Med 2003; 139: 493-498.
  27. Atkins D, Briss PA, Eccles M et al. Systems for grading the quality of evidence and the strength of recommendations II: pilot study of a new system. BMC Health Serv Res 2005; 5: 25.
  28. Levin A, Bakris GL, Molitch M et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71: 31-38.
  29. Vassalotti JA, Uribarri J, Chen SC et al. Trends in mineral metabolism: Kidney Early Evaluation Program (KEEP) and the National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis 2008; 51: S56-68.
  30. Melamed ML, Eustace JA, Plantinga LC et al. Third-generation parathyroid hormone assays and all-cause mortality in incident dialysis patients: the CHOICE study. Nephrol Dial Transplant 2008; 23: 1650-1658.
  31. Regidor DL, Kovesdy CP, Mehrotra R et al. Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J Am Soc Nephrol 2008; 19: 2193-2203.
  32. Blayney MJ, Pisoni RL, Bragg-Gresham JL et al. High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death. Kidney Int 2008; 74: 655-63.
  33. Tentori F, Blayney MJ, Albert JM et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008; 52: 519-530.
  34. Norman ME, Mazur AT, Borden St et al. Early diagnosis of juvenile renal osteodystrophy. J Pediatr 1980; 97: 226-232.
  35. Chinali M, de Simone G, Matteucci MC et al. Reduced systolic myocardial function in children with chronic renal insufficiency. J Am Soc Nephrol 2007; 18: 593-598.
  36. Hollis BW. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr 2005; 135: 317-322.
  37. Hollis BW. Assessment of vitamin D status and definition of a normal circulating range of 25-hydroxyvitamin D. Curr Opin Endocrinol Diabetes Obes 2008; 15: 489-494.
  38. Heaney RP. Optimal vitamin D status. J Bone Miner Res 2009; 24: 755.
  39. Steingrimsdottir L, Gunnarsson O, Indridason OS et al. Relationship between serum parathyroid hormone levels, vitamin D sufficiency, and calcium intake. JAMA 2005; 294: 2336-2341.
  40. Adami S, Viapiana O, Gatti D et al. Relationship between serum parathyroid hormone, vitamin D sufficiency, age, and calcium intake. Bone 2008; 42: 267-270.
  41. Holick MF. Vitamin D for health and in chronic kidney disease. Semin Dial 2005; 18: 266-275.
  42. Hollis BW, Wagner CL. Normal serum vitamin D levels. N Engl J Med 2005; 352: 515-516.
  43. Giovannucci E. Vitamin D status and cancer incidence and mortality. Adv Exp Med Biol 2008; 624: 31-42.
  44. Simon JA. Review: vitamin D supplementation decreases all-cause mortality in adults and older people. Evid Based Med 2008; 13: 47.
  45. Wolf M, Shah A, Gutierrez O et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007; 72: 1004-1013.
  46. Lappe JM, Travers-Gustafson D, Davies KM et al. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 2007; 85: 1586-1591.
  47. Gonzalez EA, Sachdeva A, Oliver DA et al. Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol 2004; 24: 503-510.
  48. 48. LaClair RE, Hellman RN, Karp SL et al. Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis 2005; 45: 1026-1033.
  49. Gutierrez OM, Isakova T, Andress DL et al. Prevalence and severity of disordered mineral metabolism in Blacks with chronic kidney disease. Kidney Int 2008; 73: 956-962.
  50. Ketteler M, Brandenburg V, Jahnen-Dechent W et al. Do not be misguided by guidelines: the calcium x phosphate product can be a Trojan horse. Nephrol Dial Transplant 2005; 20: 673-677.
  51. O'Neill WC. The fallacy of the calcium-phosphorus product. Kidney Int 2007; 72: 792-796.
  52. Parfitt AM. Bone and plasma calcium homeostasis. Bone 1987; 8(Suppl 1): S1-8.
  53. Gauci C, Moranne O, Fouqueray B et al. Pitfalls of measuring total blood calcium in patients with CKD. J Am Soc Nephrol 2008; 19: 1592-1598.
  54. Labriola L, Wallemacq P, Gulbis B et al. The impact of the assay for measuring albumin on corrected ('adjusted') calcium concentrations. Nephrol Dial Transplant 2009; 24: 1834-1838.
  55. Portale AA, Halloran BP, Morris Jr RC. Dietary intake of phosphorus modulates the circadian rhythm in serum concentration of phosphorus. Implications for the renal production of 1,25-dihydroxyvitamin D. J Clin Invest 1987; 80: 1147-1154.
  56. de Boer IH, Rue TC, Kestenbaum B. Serum phosphorus concentrations in the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2009; 53: 399-407.
  57. Worcester EM, Gillen DL, Evan AP et al. Evidence that postprandial reduction of renal calcium reabsorption mediates hypercalciuria of patients with calcium nephrolithiasis. Am J Physiol 2007; 292: F66-75.
  58. Trivedi H, Moore H, Atalla J. Lack of significant circadian and post-prandial variation in phosphate levels in subjects receiving chronic hemodialysis therapy. J Nephrol 2005; 18: 417-422.
  59. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007; 117: 4003-4008.
  60. Schmitt CP, Huber D, Mehls O et al. Altered instantaneous and calcium-modulated oscillatory PTH secretion patterns in patients with secondary hyperparathyroidism. J Am Soc Nephrol 1998; 9: 1832-1844.
  61. Endres DB, Villanueva R, Sharp Jr CF et al. Measurement of parathyroid hormone. Endocrinol metab clin North Am 1989; 18: 611-629.
  62. Gao P, D'Amour P. Evolution of the parathyroid hormone (PTH) assay--importance of circulating PTH immunoheterogeneity and of its regulation. Clin lab 2005; 51: 21-29.
  63. Slatopolsky E, Finch J, Clay P et al. A novel mechanism for skeletal resistance in uremia. Kidney Int 2000; 58: 753-761.
  64. Malluche HH, Mawad H, Trueba D et al. Parathyroid hormone assays--evolution and revolutions in the care of dialysis patients. Clin Nephrol 2003; 59: 313-318.
  65. Huan J, Olgaard K, Nielsen LB et al. Parathyroid hormone 7-84 induces hypocalcemia and inhibits the parathyroid hormone 1-84 secretory response to hypocalcemia in rats with intact parathyroid glands. J Am Soc Nephrol 2006; 17: 1923-1930.
  66. Souberbielle JC, Friedlander G, Cormier C. Practical considerations in PTH testing. Clin Chim Acta 2006; 366: 81-89.
  67. Coen G, Bonucci E, Ballanti P et al. PTH 1-84 and PTH '7-84' in the noninvasive diagnosis of renal bone disease. Am J Kidney Dis 2002; 40: 348-354.
  68. Reichel H, Esser A, Roth H-J et al. Influence of PTH assay methodology on differential diagnosis of renal bone disease. Nephrol Dial Transplant 2003; 18: 759-768.
  69. Monier-Faugere MC, Geng Z, Mawad H et al. Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients. Kidney Int 2001; 60: 1460-1468.
  70. Moe SM, Sprague SM. Chapter 52: Mineral bone disorders in chronic kidney disease. In: Brenner and Rector's The Kidney, 8th edn. WB Saunders Company: Philadelphia, PA, 2007, pp 1784-1807.
  71. Holmes DT, Levin A, Forer B et al. Preanalytical influences on DPC IMMULITE 2000 intact PTH assays of plasma and serum from dialysis patients. Clin Chem 2005; 51: 915-917.
  72. Joly D, Drueke TB, Alberti C et al. Variation in serum and plasma PTH levels in second-generation assays in hemodialysis patients: a cross-sectional study. Am J Kidney Dis 2008; 51: 987-995.
  73. Hollis BW, Napoli JL. Improved radioimmunoassay for vitamin D and its use in assessing vitamin D status. Clin Chem 1985; 31: 1815-1819.
  74. Ersfeld DL, Rao DS, Body JJ et al. Analytical and clinical validation of the 25 OH vitamin D assay for the LIAISON automated analyzer. Clin Biochem 2004; 37: 867-874.
  75. Saenger AK, Laha TJ, Bremner DE et al. Quantification of serum 25-hydroxyvitamin D(2) and D(3) using HPLC-tandem mass spectrometry and examination of reference intervals for diagnosis of vitamin D deficiency. Am J Clin Pathol 2006; 125: 914-920.
  76. Tsugawa N, Suhara Y, Kamao M et al. Determination of 25-hydroxyvitamin D in human plasma using high-performance liquid chromatography--tandem mass spectrometry. Anal Chem 2005; 77: 3001-3007.
  77. Hollis BW. Editorial: The determination of circulating 25-hydroxyvitamin D: no easy task. J Clin Endocrinol Metab 2004; 89: 3149-3151.
  78. Holick MF, Biancuzzo RM, Chen TC et al. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab 2008; 93: 677-681.
  79. Binkley N, Krueger D, Gemar D et al. Correlation among 25-hydroxy-vitamin D assays. J Clin Endocrinol Metab 2008; 93: 1804-1808.
  80. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol 2005; 289: F8-28.
  81. Pendras JP, Erickson RV. Hemodialysis: a successful therapy for chronic uremia. Ann Intern Med 1966; 64: 293-311.
  82. Alem AM, Sherrard DJ, Gillen DL et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 2000; 58: 396-399.
  83. Crans GG, Genant HK, Krege JH. Prognostic utility of a semiquantitative spinal deformity index. Bone 2005; 37: 175-179.
  84. Klotzbuecher CM, Ross PD, Landsman PB et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000; 15: 721-739.
  85. Lindsay R, Silverman SL, Cooper C et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001; 285: 320-323.
  86. Black DM, Thompson DE. The effect of alendronate therapy on osteoporotic fracture in the vertebral fracture arm of the Fracture Intervention Trial. Int J Clin Pract 1999; 101(Suppl): 46-50.
  87. Kanis JA, Borgstrom F, De Laet C et al. Assessment of fracture risk. Osteoporos Int 2005; 16: 581-589.
  88. Nevitt MC, Ettinger B, Black DM et al. The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med 1998; 128: 793-800.
  89. Danese MD, Kim J, Doan QV et al. PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis 2006; 47: 149-156.
  90. Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000; 36: 1115-1121.
  91. Mittalhenkle A, Gillen DL, Stehman-Breen CO. Increased risk of mortality associated with hip fracture in the dialysis population. Am J Kidney Dis 2004; 44: 672-679.
  92. Kaneko TM, Foley RN, Gilbertson DT et al. Clinical epidemiology of long-bone fractures in patients receiving hemodialysis. Clin Orthop Relat Res 2007; 457: 188-193.
  93. Lindergard B Johnell O, Nilsson BE. Studies of bone morphology, bone densitometry, and laboratory data in patients on maintenance hemodialysis treatment. Nephron 1985; 39: 122-129.
  94. Andrade MC, Carvalhaes JT, Carvalho AB et al. Bone mineral density and bone histomorphometry in children on long-term dialysis. Pediatr Nephrol 2007; 22: 1767-1772.
  95. Ziolkowska H, Paniczyk-Tomaszewska M, Debinski A et al. Bone biopsy results and serum bone turnover parameters in uremic children. Acta Paediatr 2000; 89: 666-671.
  96. Yalcinkaya F, Ince E, Tumer N et al. Spectrum of renal osteodystrophy in children on continuous ambulatory peritoneal dialysis. Pediatr Int 2000; 42: 53-57.
  97. Hamdy NA, Kanis JA, Beneton MN et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 1995; 310: 358-363.
  98. Spasovski GB, Sikole A, Gelev S et al. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. Nephrol Dial Transplant 2006; 21: 2217-2224.
  99. Joffe P, Heaf JG, Hyldstrup L. Osteocalcin: a non-invasive index of metabolic bone disease in patients treated by CAPD. Kidney Int 1994; 46: 838-846.
  100. Sanchez C, Lopez-Barea F, Sanchez-Cabezudo J et al. Low vs standard calcium dialysate in peritoneal dialysis: differences in treatment, biochemistry and bone histomorphometry. A randomized multicentre study. Nephrol Dial Transplant 2004; 19: 1587-1593.
  101. Baker LR, Muir JW, Sharman VL et al. Controlled trial of calcitriol in hemodialysis patients. Clin Nephrol 1986; 26: 185-191.
  102. Nordal KP, Dahl E. Low dose calcitriol versus placebo in patients with predialysis chronic renal failure. J Clin Endocrinol Metab 1988; 67: 929-936.
  103. Malluche HH, Siami GA, Swanepoel C et al. Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years. Clin Nephrol 2008; 70: 284-295.
  104. Ferreira A, Frazao JM, Monier-Faugere MC et al. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol 2008; 19: 405-412.
  105. Hernandez D, Concepcion MT, Lorenzo V et al. Adynamic bone disease with negative aluminium staining in predialysis patients: prevalence and evolution after maintenance dialysis. Nephrol Dial Transplant 1994; 9: 517-523.
  106. Shin SK, Kim DH, Kim HS et al. Renal osteodystrophy in pre-dialysis patients: ethnic difference? Perit Dial Int 1999; 19(Suppl 2): S402-407.
  107. Spasovski GB, Bervoets AR, Behets GJ et al. Spectrum of renal bone disease in end-stage renal failure patients not yet on dialysis. Nephrol Dial Transplant 2003; 18: 1159-1166.
  108. Coen G, Ballanti P, Bonucci E et al. Renal osteodystrophy in predialysis and hemodialysis patients: comparison of histologic patterns and diagnostic predictivity of intact PTH. Nephron 2002; 91: 103-111.
  109. Changsirikulchai S, Domrongkitchaiporn S, Sirikulchayanonta V et al. Renal osteodystrophy in Ramathibodi Hospital: histomorphometry and clinical correlation. J Med Assoc Thai 2000; 83: 1223-1232.
  110. Coen G, Ballanti P, Fischer MS et al. Serum leptin in dialysis renal osteodystrophy. Am J Kidney Dis 2003; 42: 1036-1042.
  111. Coen G, Ballanti P, Balducci A et al. Serum osteoprotegerin and renal osteodystrophy. Nephrol Dial Transplant 2002; 17: 233-238.
  112. Coen G, Mazzaferro S, Ballanti P et al. Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: a cross-sectional study. Nephrol Dial Transplant 1996; 11: 813-819.
  113. Piraino B, Chen T, Cooperstein L et al. Fractures and vertebral bone mineral density in patients with renal osteodystrophy. Clin Nephrol 1988; 30: 57-62.
  114. Araujo SM, Ambrosoni P, Lobao RR et al. The renal osteodystrophy pattern in Brazil and Uruguay: an overview. Kidney Int 2003; 63(Suppl 85): S54-56.
  115. Gerakis A, Hadjidakis D, Kokkinakis E et al. Correlation of bone mineral density with the histological findings of renal osteodystrophy in patients on hemodialysis. J Nephrol 2000; 13: 437-443.
  116. London GM, Marty C, Marchais SJ et al. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004; 15: 1943-1951.
  117. London GM, Marchais SJ, Guerin AP et al. Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol 2008; 19: 1827-1835.
  118. Barreto DV, Barreto FC, Carvalho AB et al. Coronary calcification in hemodialysis patients: the contribution of traditional and uremia-related risk factors. Kidney Int 2005; 67: 1576-1582.
  119. Barreto DV, Barreto Fde C, Carvalho AB et al. Association of changes in bone remodeling and coronary calcification in hemodialysis patients: a prospective study. Am J Kidney Dis 2008; 52: 1139-1150.
  120. Jamal SA, Hayden JA, Beyene J. Low bone mineral density and fractures in long-term hemodialysis patients: a meta-analysis. Am J Kidney Dis 2007; 49: 674-681.
  121. Nottestad SY, Baumel JJ, Kimmel DB et al. The proportion of trabecular bone in human vertebrae. J Bone Miner Res 1987; 2: 221-229.
  122. Klawansky S, Komaroff E, Cavanaugh Jr PF et al. Relationship between age, renal function and bone mineral density in the US population. Osteoporos Int 2003; 14: 570-576.
  123. Zhang QL, Rothenbacher D. Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health 2008; 8: 117.
  124. Jassal SK, von Muhlen D, Barrett-Connor E. Measures of renal function, BMD, bone loss, and osteoporotic fracture in older adults: the Rancho Bernardo study. J Bone Miner Res 2007; 22: 203-210.
  125. Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-1441.
  126. Miller PD, Roux C, Boonen S et al. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res 2005; 20: 2105-2115.
  127. Jamal SA, Bauer DC, Ensrud KE et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the Fracture Intervention Trial. J Bone Miner Res 2007; 22: 503-508.
  128. Cohn SH, Cinque TJ, Dombrowski CS et al. Determination of body composition by neutron activation analysis in patient with renal failure. J Lab Clin Med 1972; 79: 978-994.
  129. Griffiths HJ, Zimmerman RE, Bailey G et al. The use of photon absorptiometry in the diagnosis of renal osteodystrophy. Radiology 1973; 109: 277-281.
  130. Cohn SH, Ellis KJ, Caselnova RC et al. Correlation of radial bone mineral content with total body calcium in chronic renal failure. J Lab Clin Med 1975; 86: 910-919.
  131. Parfitt AM, Oliver I, Walczak N et al. The effect of chronic renal failure and maintenance hemodialysis on bone mineral content of the radius. AJR Am J Roentgenol 1976; 126: 1292-1293.
  132. Rickers H, Nielsen AH, Smith Pederson R et al. Bone mineral loss during maintenance hemodialysis. Acta Med Scand 1978; 204: 263-267.
  133. Aird EGA, Peerides AM. Photon absorptiometry in hemodialysis and transplant patients in Newcastle upon Tyne, England. In: Mazess RB (ed) Proceedings of the Fourth International Conference on Bone Measurement, Ontario, Canada, 1978. Published by US Department of Health and Human Services, Bethesda, MD, NIH Publication No. 80-1938, 1980, pp 217-230.
  134. Bailey RR, Stokes A, Mazess R. Bone mineral content of patients on hemodialysis and following renal transplantation. In: Mazess RB (ed) Proceedings of the Fourth International Conference on Bone Measurement, Ontario, Canada, 1978. Published by US Department of Health and Human Services, Bethesda, MD, NIH Publication No. 80-1938, 1980, pp 211-216.
  135. Heaf JG, Nielsen LP, Mogensen NB. Use of bone mineral content determination in the evaluation of osteodystrophy among hemodialysis patients. Nephron 1983; 35: 103-107.
  136. Rickers H, Christensen M, Rodbro P. Bone mineral content in patients on prolonged maintenance hemodialysis: a three year follow-up study. Clin Nephrol 1983; 20: 302-307.
  137. Eastell R, Kennedy NSJ, Smith MA et al. Changes in total body calcium after renal transplantation: effect of low-dose steroid regime. Nephron 1985; 40: 139-142.
  138. Lindergard B, Johnell O, Nilsson BE et al. Studies of bone morphology, bone densitometry, and laboratory data in patients on maintenance hemodialysis treatment. Nephron 1985; 39: 122-129.
  139. Marumo F, Sakurai K, Sato N et al. Deranged mineral content in the bone of patients with chronic renal failure, estimated by computed tomography. Int J Artif Organs 1985; 8: 95-100.
  140. Schuster VL, Chesnut CH, Baylink DJ et al. Calcium balance in uremia: longitudinal study of long-term survivors. Nephron 1985; 41: 132-140.
  141. Eeckhout E, Verbeelen D, Sennesael J et al. Monitoring of bone mineral content in patients on regular hemodialysis. Nephron 1989; 52: 158-161.
  142. Julian BA, Laskow DA, Dubovsky J et al. Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med 1991; 325: 544-550.
  143. Asaka M, LIida H, Entani C et al. Total and regional bone mineral density by dual photon absorptiometry in patients on maintenance hemodialysis. Clin Nephrol 1992; 38: 149-153.
  144. Chan TM, Pun KK, Cheng IK. Total and regional bone densities in dialysis patients. Nephrol Dial Transplant 1992; 7: 835-839.
  145. Gabay C, Ruedin P, Slosman D et al. Bone mineral density in patients with end-stage renal failure. Am J Nephrol 1993; 13: 115-123.
  146. Hutchison AJ, Whitehouse RW, Boulton HF et al. Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease. Kidney Int 1993; 44: 1071-1077.
  147. 147. Kaye M, Rosenthall L, Hill RO et al. Long-term outcome following total parathyroidectomy in patients with end-stage renal disease. Clin Nephrol 1993; 39: 192-197.
  148. 148. Moe SM, Yu BO, Sprague SM. Maintenance of bone mass in patients receiving dialytic therapy. Am J Kidney Dis 1993; 22: 300-307.
  149. 149. Lechleitner P, Krimbacker E, Genser N et al. Bone mineral densitometry in dialyzed patients: quantitative computed tomography versus dual photon absorptiometry. Bone 1994; 15: 387-391.
  150. 150. Ruedin P, Rizzoli R, Slosman D et al. Effects of oral calcitriol on bone mineral density in patients with end-stage renal failure. Kidney Int 1994; 45: 245-252.
  151. 151. Mottet JJ, Horber FF, Casez JP et al. Evidence for preservation of cortical bone mineral density in patients on continuous ambulatory peritoneal dialysis. J Bone Miner Res 1996; 11: 96-104.
  152. 152. Stein MS, Packham DK, Ebeling PR et al. Prevalence and risk factors for osteopenia in dialysis patients. Am J Kidney Dis 1996; 28: 515-522.
  153. 153. Yamaguchi T, Kanno E, Tsubota J et al. Retrospective study on the usefulness of radius and lumbar bone density in the separation of hemodialysis patients with fractures from those without fractures. Bone 1996; 19: 549-555.
  154. 154. Spindler A, Paz S, Berman A et al. Muscular strength and bone mineral density in haemodialysis patients. Nephrol Dial Transplant 1997; 12: 128-132.
  155. 155. Lippuner K, Casez JP, Horber FF et al. Effects of deflazacort versus prednisone on bone mass, body composition, and lipid profile: a randomized, double blind study in kidney transplant patients. J Clin Endocrinol Metab 1998; 83: 3795-3802.
  156. 156. Russo CR, Taccetti G, Caneva P et al. Volumetric bone density and geometry assessed by peripheral quantitative computed tomography in uremic patients on maintenance hemodialysis. Osteoporos Int 1998; 8: 443-448.
  157. 157. Atsumi K, Kushida K, Yamazaki K et al. Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 1999; 33: 287-293.
  158. 158. Stehman-Breen CO, Sherrard D, Walker A et al. Racial differences in bone mineral density and bone loss among end-stage renal disease patients. Am J Kidney Dis 1999; 33: 941-946.
  159. 159. Taal MW, Masud T, Green D et al. Risk factors for reduced bone density in haemodialysis patients. Nephrol Dial Transplant 1999; 14: 1922-1928.
  160. 160. Arici M, Erturk H, Altun B et al. Bone mineral density in haemodialysis patients: a comparative study of dual-energy X-ray absorptiometry and quantitative ultrasound. Nephrol Dial Transplant 2000; 15: 1847-1851.
  161. 161. Fan SL, Almond MK, Ball E et al. Pamidronate therapy as prevention of bone loss following renal transplantation. Kidney Int 2000; 57: 684-690.
  162. 162. Kokado Y, Takahara S, Ichimaru N et al. Factors influencing vertebral bone density after renal transplantation. Transpl Int 2000; 13(Suppl 1): S431-435.
  163. 163. Barnas U, Schmidt A, Seidl G et al. A comparison of quantitative computed tomography and dual X-ray absorptiometry for evaluation of bone mineral density in patients on chronic hemodialysis. Am J Kidney Dis 2001; 37: 1247-1252.
  164. 164. Baszko-Blaszyk D, Grzegorzewska AE, Horst-Sikorska W et al. Bone mass in chronic renal insufficiency patients treated with continuous ambulatory peritoneal dialysis. Adv Perit Dial 2001; 17: 109-113.
  165. 165. Grotz W, Nagel C, Poeschel D et al. Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol 2001; 12: 1530-1537.
  166. 166. Casez JP, Lippuner K, Horber FF et al. Changes in bone mineral density over 18 months following kidney transplantation: the respective roles of prednisone and parathyroid hormone. Nephrol Dial Transplant 2002; 17: 1318-1326.
  167. 167. Haas M, Leko-Mohr Z, Roschger P et al. Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients. Am J Kidney Dis 2002; 39: 580-586.
  168. 168. Hampson G, Vaja S, Evans C et al. Comparison of the humoral markers of bone turnover and bone mineral density in patients on haemodialysis and continuous ambulatory peritoneal dialysis. Nephron 2002; 91: 94-102.
  169. 169. Kaji H, Suzuki M, Yano S et al. Risk factors for hip fracture in hemodialysis patients. Am J Nephrol 2002; 22: 325-331.
  170. 170. Pecovnik Balon B, Hojs R, Zavratnik A et al. Bone mineral density in patients beginning hemodialysis treatment. Am J Nephrol 2002; 22: 14-17.
  171. 171. Ghazali A, Grados F, Oprisiu R et al. Bone mineral density directly correlates with elevated serum leptin in haemodialysis patients. Nephrol Dial Transplant 2003; 18: 1882-1890.
  172. 172. Kato A, Odamaki M, Yamamoto T et al. Influence of body composition on 5 year mortality in patients on regular haemodialysis. Nephrol Dial Transplant 2003; 18: 333-340.
  173. 173. Mikuls TR, Julian BA, Bartolucci A et al. Bone mineral density changes within six months of renal transplantation. Transplantation 2003; 75: 49-54.
  174. 174. Nakashima A, Yorioka N, Tanji C et al. Bone mineral density may be related to atherosclerosis in hemodialysis patients. Osteoporos Int 2003; 14: 369-373.
  175. 175. Urena P, Bernard-Poenaru O, Ostertag A et al. Bone mineral density, biochemical markers and skeletal fractures in haemodialysis patients. Nephrol Dial Transplant 2003; 18: 2325-2331.
  176. 176. Zayour D, Daouk M, Medawar W et al. Predictors of bone mineral density in patients on hemodialysis. Transplant Proc 2004; 36: 1297-1301.
  177. 177. Crisafulli A, Romeo A, Floccari F et al. Osteoprotegerin and bone mineral density in hemodiafiltration patients. Ren Fail 2005; 27: 531-539.
  178. 178. Maeno Y, Inaba M, Okuno S et al. Serum concentrations of cross-linked N-telopeptides of type I collagen: new marker for bone resorption in hemodialysis patients. Clin Chem 2005; 51: 2312-2317.
  179. 179. Wetmore JB, Benet LZ, Kleinstuck D et al. Effects of short-term alendronate on bone mineral density in haemodialysis patients. Nephrology (Carlton) 2005; 10: 393-399.
  180. 180. Elder GJ, Mackun K. 25-Hydroxyvitamin D deficiency and diabetes predict reduced BMD in patients with chronic kidney disease. J Bone Miner Res 2006; 21: 1778-1784.
  181. 181. Ersoy FF, Passadakis SP, Tam P et al. Bone mineral density and its correlation with clinical and laboratory factors in chronic peritoneal dialysis patients. J Bone Miner Metab 2006; 24: 79-86.
  182. 182. Nakashima A, Yorioka N, Doi S et al. Osteoprotegerin and bone mineral density in hemodialysis patients. Osteoporos Int 2006; 17: 841-846.
  183. 183. Kanis JA, Gluer CC. An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation. Osteoporos Int 2000; 11: 192-202.
  184. 184. Johnell O, Kanis JA, Oden A et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res 2005; 20: 1185-1194.
  185. 185. Kanis JA, Johnell O, Oden A et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008; 19: 385-397.
  186. 186. Kanis JA, Oden A, Johnell O et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 2007; 18: 1033-1046.
  187. 187. Clark EM, Ness AR, Bishop NJ et al. Association between bone mass and fractures in children: a prospective cohort study. J Bone Miner Res 2006; 21: 1489-1495.
  188. 188. Jamal SA, Chase C, Goh YI et al. Bone density and heel ultrasound testing do not identify patients with dialysis-dependent renal failure who have had fractures. Am J Kidney Dis 2002; 39: 843-849.
  189. 189. Negri AL, Barone R, Quiroga MA et al. Bone mineral density: serum markers of bone turnover and their relationships in peritoneal dialysis. Perit Dial Int 2004; 24: 163-168.
  190. 190. Fontaine MA, Albert A, Dubois B et al. Fracture and bone mineral density in hemodialysis patients. Clin Nephrol 2000; 54: 218-226.
  191. 191. Inaba M, Okuno S, Kumeda Y et al. Increased incidence of vertebral fracture in older female hemodialyzed patients with type 2 diabetes mellitus. Calcif Tissue Int 2005; 76: 256-260.
  192. 192. Jamal SA, Gilbert J, Gordon C et al. Cortical pQCT measures are associated with fractures in dialysis patients. J Bone Miner Res 2006; 21: 543-548.
  193. 193. Dukas L, Schacht E, Stahelin HB. In elderly men and women treated for osteoporosis a low creatinine clearance of <65 ml/min is a risk factor for falls and fractures. Osteoporos Int 2005; 16: 1683-1690.
  194. 194. Li M, Tomlinson G, Naglie G et al. Geriatric comorbidities, such as falls, confer an independent mortality risk to elderly dialysis patients. Nephrol Dial Transplant 2008; 23: 1396-1400.
  195. Cook WL, Tomlinson G, Donaldson M et al. Falls and fall-related injuries in older dialysis patients. Clin J Am Soc Nephrol 2006; 1: 1197-1204.
  196. Desmet C, Beguin C, Swine C et al. Falls in hemodialysis patients: prospective study of incidence, risk factors, and complications. Am J Kidney Dis 2005; 45: 148-153.
  197. Torres A, Lorenzo V, Gonzalez-Posada JM. Comparison of histomorphometry and computerized tomography of the spine in quantitating trabecular bone in renal osteodystrophy. Nephron 1986; 44: 282-287.
  198. Van Eps CL, Jeffries JK, Anderson JA et al. Mineral metabolism, bone histomorphometry and vascular calcification in alternate night nocturnal haemodialysis. Nephrology (Carlton) 2007; 12: 224-233.
  199. DeVita MV, Rasenas LL, Bansal M et al. Assessment of renal osteodystrophy in hemodialysis patients. Medicine (Baltimore) 1992; 71: 284-290.
  200. Schober HC, Han ZH, Foldes AJ et al. Mineralized bone loss at different sites in dialysis patients: implications for prevention. J Am Soc Nephrol 1998; 9: 1225-1233.
  201. Boling E, Primavera C, Friedman G et al. Non-invasive measurements of bone mass in adult renal osteodystrophy. Bone 1993; 14: 409-413.
  202. Fletcher S, Jones RG, Rayner HC et al. Assessment of renal osteodystrophy in dialysis patients: use of bone alkaline phosphatase, bone mineral density and parathyroid ultrasound in comparison with bone histology. Nephron 1997; 75: 412-419.
  203. Taal MW, Roe S, Masud T et al. Total hip bone mass predicts survival in chronic hemodialysis patients. Kidney Int 2003; 63: 1116-1120.
  204. Stehman-Breen C, Anderson G, Gibson D et al. Pharmacokinetics of oral micronized beta-estradiol in postmenopausal women receiving maintenance hemodialysis. Kidney Int 2003; 64: 290-294.
  205. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218.
  206. Jadoul M, Albert JM, Akiba T et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2006; 70: 1358-1366.
  207. Mitterbauer C, Kramar R, Oberbauer R. Age and sex are sufficient for predicting fractures occurring within 1 year of hemodialysis treatment. Bone 2007; 40: 516-521.
  208. Ersoy FF. Osteoporosis in the elderly with chronic kidney disease. Int Urol Nephrol 2007; 39: 321-331.
  209. Rudser KD, de Boer IH, Dooley A et al. Fracture risk after parathyroidectomy among chronic hemodialysis patients. J Am Soc Nephrol 2007; 18: 2401-2407.
  210. de Vernejoul MC, Kuntz D, Miravet L et al. Bone histomorphometric reproducibility in normal patients. Calcif Tissue Int 1981; 33: 369-374.
  211. Andress DL, Endres DB, Maloney NA et al. Comparison of parathyroid hormone assays with bone histomorphometry in renal osteodystrophy. J Clin Endocrinol Metab 1986; 63: 1163-1169.
  212. Andress DL, Norris KC, Coburn JW et al. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 1989; 321: 274-279.
  213. Quarles LD, Lobaugh B, Murphy G. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 1992; 75: 145-150.
  214. Sherrard DJ, Hercz G, Pei Y et al. The spectrum of bone disease in end-stage renal failure--an evolving disorder. Kidney Int 1993; 43: 436-442.
  215. Torres A, Lorenzo V, Hernandez D et al. Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH. Kidney Int 1995; 47: 1434-1442.
  216. Wang M, Hercz G, Sherrard DJ et al. Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis 1995; 26: 836-844.
  217. Mazzaferro S, Pasquali M, Ballanti P et al. Diagnostic value of serum peptides of collagen synthesis and degradation in dialysis renal osteodystrophy. Nephrol Dial Transplant 1995; 10: 52-58.
  218. Gerakis A, Hutchison AJ, Apostolou T et al. Biochemical markers for non-invasive diagnosis of hyperparathyroid bone disease and adynamic bone in patients on haemodialysis. Nephrol Dial Transplant 1996; 11: 2430-2438.
  219. Urena P, Hruby M, Ferreira A et al. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol 1996; 7: 506-512.
  220. Coen G, Ballanti P, Bonucci E et al. Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients. Nephrol Dial Transplant 1998; 13: 2294-2302.
  221. Carmen Sanchez M, Auxiliadora Bajo M, Selgas R et al. Parathormone secretion in peritoneal dialysis patients with adynamic bone disease. Am J Kidney Dis 2000; 36: 953-961.
  222. Bervoets AR, Spasovski GB, Behets GJ et al. Useful biochemical markers for diagnosing renal osteodystrophy in predialysis end-stage renal failure patients. Am J Kidney Dis 2003; 41: 997-1007.
  223. Gal-Moscovici A, Popovtzer MM. New worldwide trends in presentation of renal osteodystrophy and its relationship to parathyroid hormone levels. Clin Nephrol 2005; 63: 284-289.
  224. Coen G, Ballanti P, Balducci A et al. Renal osteodystrophy: alpha-Heremans Schmid glycoprotein/fetuin-A, matrix GLA protein serum levels, and bone histomorphometry. Am J Kidney Dis 2006; 48: 106-113.
  225. McCarthy JT, Klee GG, Kao PC et al. Serum bioactive parathyroid hormone in hemodialysis patients. J Clin Endocrinol Metab 1989; 68: 340-345.
  226. Qi Q, Monier-Faugere MC, Geng Z et al. Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis 1995; 26: 622-631.
  227. Couttenye MM, D'Haese PC, Van Hoof VO et al. Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in haemodialysis patients. Nephrol Dial Transplant 1996; 11: 1065-1072.
  228. Lehmann G, Ott U, Kaemmerer D et al. Bone histomorphometry and biochemical markers of bone turnover in patients with chronic kidney disease stages 3-5. Clin Nephrol 2008; 70: 296-305.
  229. Barreto FC, Barreto DV, Moyses RM et al. K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. Kidney Int 2008; 73: 771-777.
  230. Hutchison AJ, Whitehouse RW, Boulton HF et al. Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease. Kidney Int 1993; 44: 1071-1077.
  231. Barreto FC, Barreto DV, Moyses RM et al. Osteoporosis in hemodialysis patients revisited by bone histomorphometry: a new insight into an old problem. Kidney Int 2006; 69: 1852-1857.
  232. Jehle PM, Ostertag A, Schulten K et al. Insulin-like growth factor system components in hyperparathyroidism and renal osteodystrophy. Kidney Int 2000; 57: 423-436.
  233. Rix M, Andreassen H, Eskildsen P et al. Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int 1999; 56: 1084-1093.
  234. Tsuchida T, Ishimura E, Miki T et al. The clinical significance of serum osteocalcin and N-terminal propeptide of type I collagen in predialysis patients with chronic renal failure. Osteoporos Int 2005; 16: 172-179.
  235. Obatake N, Ishimura E, Tsuchida T et al. Annual change in bone mineral density in predialysis patients with chronic renal failure: significance of a decrease in serum 1,25-dihydroxy-vitamin D. J Bone Miner Metab 2007; 25: 74-79.
  236. Ueda M, Inaba M, Okuno S et al. Clinical usefulness of the serum N-terminal propeptide of type I collagen as a marker of bone formation in hemodialysis patients. Am J Kidney Dis 2002; 40: 802-809.
  237. Wittersheim E, Mesquita M, Demulder A et al. OPG, RANK-L, bone metabolism, and BMD in patients on peritoneal dialysis and hemodialysis. Clin Biochem 2006; 39: 617-622.
  238. Sit D, Kadiroglu AK, Kayabasi H et al. Relationship between bone mineral density and biochemical markers of bone turnover in hemodialysis patients. Adv Ther 2007; 24: 987-995.
  239. Doumouchtsis KK, Kostakis AI, Doumouchtsis SK et al. Associations between osteoprotegerin and femoral neck BMD in hemodialysis patients. J Bone Miner Metab 2008; 26: 66-72.
  240. Urena P, De Vernejoul MC. Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int 1999; 55: 2141-2156.
  241. Ivaska KK, Gerdhem P, Akesson K et al. Effect of fracture on bone turnover markers: a longitudinal study comparing marker levels before and after injury in 113 elderly women. J Bone Miner Res 2007; 22: 1155-1164.
  242. Rogers A, Eastell R. Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab 2005; 90: 6323-6331.
  243. Gutierrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592.
  244. Garnero P, Sornay-Rendu E, Claustrat B et al. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 2000; 15: 1526-1536.
  245. Johnell O, Oden A, De Laet C et al. Biochemical indices of bone turnover and the assessment of fracture probability. Osteoporos Int 2002; 13: 523-526.
  246. . Gerdhem P, Ivaska KK, Alatalo SL et al. Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res 2004; 19: 386-393.
  247. Bauer DC, Black DM, Garnero P et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 2004; 19: 1250-1258.
  248. Bauer DC, Garnero P, Hochberg MC et al. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res 2006; 21: 292-299.
  249. Sarkar S, Reginster JY, Crans GG et al. Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res 2004; 19: 394-401.
  250. Fahrleitner-Pammer A, Herberth J, Browning SR et al. Bone markers predict cardiovascular events in chronic kidney disease. J Bone Miner Res 2008; 23: 1850-1858.
  251. Looker AC, Bauer DC, Chesnut III CH et al. Clinical use of biochemical markers of bone remodeling: current status and future directions. Osteoporos Int 2000; 11: 467-480.
  252. Talley L, Stablein DM. North American Pediatric Renal Trials and Collaborative Studies: NAPRTCS 2006 Annual Report. NAPRTCS: Boston, MA, 2006, pp 1-270.
  253. Vliegenthart R, Hollander M, Breteler MM et al. Stroke is associated with coronary calcification as detected by electron-beam CT: the Rotterdam Coronary Calcification Study. Stroke 2002; 33: 462-465.
  254. Vliegenthart R, Oudkerk M, Song B et al. Coronary calcification detected by electron-beam computed tomography and myocardial infarction. The Rotterdam Coronary Calcification Study. Eur Heart J 2002; 23: 1596-1603.
  255. Oei HH, Vliegenthart R, Deckers JW et al. The association of Rose questionnaire angina pectoris and coronary calcification in a general population: the Rotterdam Coronary Calcification Study. Ann Epidemiol 2004; 14: 431-436.
  256. McCullough PA, Agrawal V, Danielewicz E et al. Accelerated atherosclerotic calcification and Monckeberg's sclerosis: a continuum of advanced vascular pathology in chronic kidney disease. Clin J Am Soc Nephrol 2008; 3: 1585-1598.
  257. Amann K. Media calcification and intima calcification are distinct entities in chronic kidney disease. Clin J Am Soc Nephrol 2008; 3: 1599-1605.
  258. Schwarz U, Buzello M, Ritz E et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 2000; 15: 218-223.
  259. Gross ML, Meyer HP, Ziebart H et al. Calcification of coronary intima and media: immunohistochemistry, backscatter imaging, and x-ray analysis in renal and nonrenal patients. Clin J Am Soc Nephrol 2007; 2: 121-134.
  260. Moe SM, Duan D, Doehle BP et al. Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. Kidney Int 2003; 63: 1003-1011.
  261. Ibels LS, Alfrey AC, Huffer WE et al. Arterial calcification and pathology in uremic patients undergoing dialysis. Am J Med 1979; 66: 790-796.
  262. Giachelli CM. Vascular calcification mechanisms. J Am Soc Nephrol 2004; 15: 2959-2964.
  263. Cozzolino M, Dusso AS, Liapis H et al. The effects of sevelamer hydrochloride and calcium carbonate on kidney calcification in uremic rats. J Am Soc Nephrol 2002; 13: 2299-2308.
  264. Mathew S, Lund RJ, Strebeck F et al. Reversal of the adynamic bone disorder and decreased vascular calcification in chronic kidney disease by sevelamer carbonate therapy. J Am Soc Nephrol 2007; 18: 122-130.
  265. Block GA, Raggi P, Bellasi A et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007; 71: 438-441.
  266. Suki WN, Zabaneh R, Cangiano JL et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007; 72: 1130-1137.
  267. St Peter WL, Liu J, Weinhandl E et al. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am J Kidney Dis 2008; 51: 445-454.
  268. Tatler GL, Baillod RA, Varghese Z et al. Evolution of bone disease over 10 years in 135 patients with terminal renal failure. BMJ 1973; 4: 315-319.
  269. Ibels LS, Stewart JH, Mahony JF et al. Deaths from occlusive arterial disease in renal allograft recipients. BMJ 1974; 3: 552-554.
  270. Ketteler M, Schlieper G, Floege J. Calcification and cardiovascular health: new insights into an old phenomenon. Hypertension 2006; 47: 1027-1034.
  271. Murshed M, Harmey D, Millan JL et al. Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone. Genes Dev 2005; 19: 1093-1104.
  272. Bellasi A, Ferramosca E, Muntner P et al. Correlation of simple imaging tests and coronary artery calcium measured by computed tomography in hemodialysis patients. Kidney Int 2006; 70: 1623-1628.
  273. Haydar AA, Covic A, Colhoun H et al. Coronary artery calcification and aortic pulse wave velocity in chronic kidney disease patients. Kidney Int 2004; 65: 1790-1794.
  274. Nitta K, Akiba T, Suzuki K et al. Assessment of coronary artery calcification in hemodialysis patients using multi-detector spiral CT scan. Hypertens Res 2004; 27: 527-533.
  275. Sigrist M, Bungay P, Taal MW et al. Vascular calcification and cardiovascular function in chronic kidney disease. Nephrol Dial Transplant 2006; 21: 707-714.
  276. Stompor T, Rajzer M, Pasowicz M et al. Coronary artery calcification, common carotid artery intima-media thickness and aortic pulse wave velocity in patients on peritoneal dialysis. Int J Artif Organs 2006; 29: 736-744.
  277. Raggi P, Bellasi A, Ferramosca E et al. Association of pulse wave velocity with vascular and valvular calcification in hemodialysis patients. Kidney Int 2007; 71: 802-807.
  278. Shroff RC, Donald AE, Hiorns MP et al. Mineral metabolism and vascular damage in children on dialysis. J Am Soc Nephrol 2007; 18: 2996-3003.
  279. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-1483.
  280. Oh KW, Nam CM, Jee SH et al. Coronary artery calcification and dietary cholesterol intake in Korean men. Acta Cardiol 2002; 57: 5-11.
  281. Ix JH, Shlipak MG, Katz R et al. Kidney function and aortic valve and mitral annular calcification in the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis 2007; 50: 412-420.
  282. Wang AY, Wang M, Woo J et al. Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study. J Am Soc Nephrol 2003; 14: 159-168.
  283. Panuccio V, Tripepi R, Tripepi G et al. Heart valve calcifications, survival, and cardiovascular risk in hemodialysis patients. Am J Kidney Dis 2004; 43: 479-484.
  284. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252.
  285. Block GA, Spiegel DM, Ehrlich J et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68: 1815-1824.
  286. Russo D, Miranda I, Ruocco C et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int 2007; 72: 1255-1261.
  287. Qunibi W, Moustafa M, Muenz LR et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 2008; 51: 952-965.
  288. Barreto DV, Barreto Fde C, de Carvalho AB et al. Phosphate binder impact on bone remodeling and coronary calcification--results from the BRiC study. Nephron Clin Pract 2008; 110: c273-283.
  289. Floege J. Calcium-containing phosphate binders in dialysis patients with cardiovascular calcifications: should we CARE-2 avoid them? Nephrol Dial Transplant 2008; 23: 3050-3052.
  290. Russo D, Corrao S, Miranda I et al. Progression of coronary artery calcification in predialysis patients. Am J Nephrol 2007; 27: 152-158.
  291. Suwelack B, Gerhardt U, Witta J et al. Effect of parathyroid hormone levels on carotid intima-media thickness after renal transplantation. Am J Hypertens 2001; 14: 1012-1018.
  292. Shroff RC, McNair R, Figg N et al. Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation 2008; 118: 1748-1757.
  293. London GM, Guerin AP, Verbeke FH et al. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 2007; 18: 613-620.
  294. Matias PJ, Ferreira C, Jorge C et al. 25-Hydroxyvitamin D3, arterial calcifications and cardiovascular risk markers in haemodialysis patients. Nephrol Dial Transplant 2009; 24: 611-618
  295. Lopez I, Aguilera-Tejero E, Mendoza FJ et al. Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol. J Am Soc Nephrol 2006; 17: 795-804.
  296. Koleganova N, Piecha G, Ritz E et al. A calcimimetic (R-568), but not calcitriol, prevents vascular remodeling in uremia. Kidney Int 2009; 75: 60-71.
  297. Ivanovski O, Nikolov IG, Joki N et al. The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE(-/-)) mice. Atherosclerosis 2009; 205: 55-62.
  298. Haffner D, Hocher B, Muller D et al. Systemic cardiovascular disease in uremic rats induced by 1,25(OH)2D3. J Hypertens 2005; 23: 1067-1075.
  299. Mizobuchi M, Finch JL, Martin DR et al. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int 2007; 72: 709-715.
  300. Lopez I, Mendoza FJ, Aguilera-Tejero E et al. The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats. Kidney Int 2008; 73: 300-307.
  301. Greenland P, Bonow RO, Brundage BH et al. ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography). Circulation 2007; 115: 402-426.
  302. Baigent C, Landray MJ, Wheeler DC. Misleading associations between cholesterol and vascular outcomes in dialysis patients: the need for randomized trials. Semin Dial 2007; 20: 498-503.
  303. Nissen SE, Tuzcu EM, Schoenhagen P et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291: 1071-1080.
  304. Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-1158.
  305. LaRosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-1435.
  306. Raggi P, Davidson M, Callister TQ et al. Aggressive versus moderate lipid-lowering therapy in hypercholesterolemic postmenopausal women: Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES). Circulation 2005; 112: 563-571.
  307. Schmermund A, Achenbach S, Budde T et al. Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: a multicenter, randomized, double-blind trial. Circulation 2006; 113: 427-437.
  308. Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int 2003; 63(Suppl 84): S207-210.
  309. Fellstrom BC, Jardine AG, Schmieder RE et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360: 1395-1407.
  310. Kestenbaum B. Phosphate metabolism in the setting of chronic kidney disease: significance and recommendations for treatment. Semin Dial 2007; 20: 286-294.
  311. Takeda E, Yamamoto H, Nishida Y et al. Phosphate restriction in diet therapy. Contrib Nephrol 2007; 155: 113-124.
  312. Sprague SM. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate. Curr Med Res Opin 2007; 23: 3167-3175.
  313. Ayus JC, Achinger SG, Mizani MR et al. Phosphorus balance and mineral metabolism with 3 h daily hemodialysis. Kidney Int 2007; 71: 336-342.
  314. Culleton BF, Walsh M, Klarenbach SW et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA 2007; 298: 1291-1299.
  315. Ganesh SK, Stack AG, Levin NW et al. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: 2131-2138.
  316. Kestenbaum B, Sampson JN, Rudser KD et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005; 16: 520-528.
  317. Block GA, Hulbert-Shearon TE, Levin NW et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617.
  318. Rodriguez-Benot A, Martin-Malo A, Alvarez-Lara MA et al. Mild hyperphosphatemia and mortality in hemodialysis patients. Am J Kidney Dis 2005; 46: 68-77.
  319. Naveh-Many T, Rahamimov R, Livni N et al. Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D. J Clin Invest 1995; 96: 1786-1793.
  320. Almaden Y, Canalejo A, Hernandez A et al. Direct effect of phosphorus on PTH secretion from whole rat parathyroid glands in vitro. J Bone Miner Res 1996; 11: 970-976.
  321. Slatopolsky E, Rutherford WE, Martin K et al. The role of phosphate and other factors on the pathogenesis of renal osteodystrophy. Adv Exp Med Biol 1977; 81: 467-475.
  322. Gal-Moscovici A, Sprague SM. Role of vitamin D deficiency in chronic kidney disease. J Bone Miner Res 2007; 22 (Suppl 2): V91-94.
  323. Giachelli CM. Vascular calcification: in vitro evidence for the role of inorganic phosphate. J Am Soc Nephrol 2003; 14: S300-304.
  324. Dhingra R, Sullivan LM, Fox CS et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007; 167: 879-885.
  325. Tonelli M, Sacks F, Pfeffer M et al. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005; 112: 2627-2633.
  326. Menon V, Greene T, Pereira AA et al. Relationship of phosphorus and calcium-phosphorus product with mortality in CKD. Am J Kidney Dis 2005; 46: 455-463.
  327. Noordzij M, Korevaar JC, Boeschoten EW et al. The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients. Am J Kidney Dis 2005; 46: 925-932.
  328. Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-780.
  329. Young EW, Albert JM, Satayathum S et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005; 67: 1179-1187.
  330. Kimata N, Albert JM, Akiba T et al. Association of mineral metabolism factors with all-cause and cardiovascular mortality in hemodialysis patients: the Japan dialysis outcomes and practice patterns study. Hemodial Int 2007; 11: 340-348.
  331. Estepa JC, Aguilera-Tejero E, Lopez I et al. Effect of phosphate on parathyroid hormone secretion in vivo. J Bone Miner Res 1999; 14: 1848-1854.
  332. Roussanne MC, Lieberherr M, Souberbielle JC et al. Human parathyroid cell proliferation in response to calcium, NPS R-467, calcitriol and phosphate. Eur J Clin Invest 2001; 31: 610-616.
  333. Jono S, McKee MD, Murry CE et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000; 87: E10-17.
  334. Toussaint N, Cooney P, Kerr PG. Review of dialysate calcium concentration in hemodialysis. Hemodial Int 2006; 10: 326-337.
  335. McIntyre CW. Calcium balance during hemodialysis. Semin Dial 2008; 21: 38-42.
  336. Hou SH, Zhao J, Ellman CF et al. Calcium and phosphorus fluxes during hemodialysis with low calcium dialysate. Am J Kidney Dis 1991; 18: 217-224.
  337. Argiles A, Kerr PG, Canaud B et al. Calcium kinetics and the long-term effects of lowering dialysate calcium concentration. Kidney Int 1993; 43: 630-640.
  338. Sigrist M, McIntyre CW. Calcium exposure and removal in chronic hemodialysis patients. J Ren Nutr 2006; 16: 41-46.
  339. Maynard JC, Cruz C, Kleerekoper M et al. Blood pressure response to changes in serum ionized calcium during hemodialysis. Ann Intern Med 1986; 104: 358-361.
  340. van der Sande FM, Cheriex EC, van Kuijk WH et al. Effect of dialysate calcium concentrations on intradialytic blood pressure course in cardiac-compromised patients. Am J Kidney Dis 1998; 32: 125-131.
  341. Jeffery EH, Abreo K, Burgess E et al. Systemic aluminum toxicity: effects on bone, hematopoietic tissue, and kidney. J Toxicol Environ Health 1996; 48: 649-665.
  342. King SW, Savory J, Wills MR. Aluminum toxicity in relation to kidney disorders. Ann Clin Lab Sci 1981; 11: 337-342.
  343. Braun J, Asmus HG, Holzer H et al. Long-term comparison of a calcium-free phosphate binder and calcium carbonate--phosphorus metabolism and cardiovascular calcification. Clin Nephrol 2004; 62: 104-115.
  344. Asmus HG, Braun J, Krause R et al. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrol Dial Transplant 2005; 20: 1653-1661.
  345. Raggi P, Bommer J, Chertow GM. Valvular calcification in hemodialysis patients randomized to calcium-based phosphorus binders or sevelamer. J Heart Valve Dis 2004; 13: 134-141.
  346. Raggi P, James G, Burke SK et al. Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis. J Bone Miner Res 2005; 20: 764-772.
  347. Kurz P, Monier-Faugere MC, Bognar B et al. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 1994; 46: 855-861.
  348. Hutchison AJ, Maes B, Vanwalleghem J et al. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract 2005; 100: c8-19.
  349. Finn WF. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol 2006; 65: 191-202.
  350. Drueke TB. Intestinal absorption of aluminium in renal failure. Nephrol Dial Transplant 2002; 17 (Suppl 2): 13-16.
  351. Zeller K, Whittaker E, Sullivan L et al. Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. N Engl J Med 1991; 324: 78-84.
  352. Lafage MH, Combe C, Fournier A et al. Ketodiet, physiological calcium intake and native vitamin D improve renal osteodystrophy. Kidney Int 1992; 42: 1217-1225.
  353. Lafage-Proust MH, Combe C, Barthe N et al. Bone mass and dynamic parathyroid function according to bone histology in nondialyzed uremic patients after long-term protein and phosphorus restriction. J Clin Endocrinol Metab 1999; 84: 512-519.
  354. Pieper AK, Haffner D, Hoppe B et al. A randomized crossover trial comparing sevelamer with calcium acetate in children with CKD. Am J Kidney Dis 2006; 47: 625-635.
  355. Tonelli M, Wiebe N, Culleton B et al. Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Nephrol Dial Transplant 2007; 22: 2856-2866.
  356. Altmann P, Barnett ME, Finn WF. Cognitive function in stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy. Kidney Int 2007; 71: 252-259.
  357. Chertow GM, Raggi P, McCarthy JT et al. The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients. Am J Nephrol 2003; 23: 307-314.
  358. Brown AJ, Finch J, Grieff M et al. The mechanism for the disparate actions of calcitriol and 22-oxacalcitriol in the intestine. Endocrinology 1993; 133: 1158-1164.
  359. Slatopolsky E, Cozzolino M, Finch JL. Differential effects of 19-nor-1,25-(OH)(2)D(2) and 1alpha-hydroxyvitamin D(2) on calcium and phosphorus in normal and uremic rats. Kidney Int 2002; 62: 1277-1284.
  360. Nakane M, Fey TA, Dixon DB et al. Differential effects of Vitamin D analogs on bone formation and resorption. J Steroid Biochem Mol Biol 2006; 98: 72-77.
  361. Cardus A, Panizo S, Parisi E et al. Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res 2007; 22: 860-866.
  362. Fryer RM, Rakestraw PA, Nakane M et al. Differential inhibition of renin mRNA expression by paricalcitol and calcitriol in C57/BL6 mice. Nephron 2007; 106: 76-81.
  363. Segersten U, Holm PK, Bjorklund P et al. 25-Hydroxyvitamin D3 1alpha-hydroxylase expression in breast cancer and use of non-1alpha-hydroxylated vitamin D analogue. Breast Cancer Res 2005; 7: R980-R986.
  364. van Driel M, Koedam M, Buurman CJ et al. Evidence for auto/paracrine actions of vitamin D in bone: 1alpha-hydroxylase expression and activity in human bone cells. FASEB J 2006; 20: 2417-2419.
  365. Somjen D, Weisman Y, Kohen F et al. 25-hydroxyvitamin D3-1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation 2005; 111: 1666-1671.
  366. Segersten U, Correa P, Hewison M et al. 25-hydroxyvitamin D(3)-1alpha-hydroxylase expression in normal and pathological parathyroid glands. J Clin Endocrinol Metab 2002; 87: 2967-2972.
  367. Brown EM. Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue. J Clin Endocrinol Metab 1983; 56: 572-581.
  368. Brown EM, Gamba G, Riccardi D et al. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 1993; 366: 575-580.
  369. Brown EM. Clinical lessons from the calcium-sensing receptor. Nat Clin Pract Endocrinol Metab 2007; 3: 122-133.
  370. Dusso AS, Arcidiacono MV, Sato T et al. Molecular basis of parathyroid hyperplasia. J Ren Nutr 2007; 17: 45-47.
  371. Bolland MJ, Barber PA, Doughty RN et al. Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. BMJ 2008; 336: 262-266.
  372. Hsia J, Heiss G, Ren H et al. Calcium/vitamin D supplementation and cardiovascular events. Circulation 2007; 115: 846-854.
  373. Sprague SM, Abboud H, Qiu P et al. Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. Clin J Am Soc Nephrol 2009; 4: 178-185.
  374. Kooienga L, Fried L, Scragg R et al. The effect of combined calcium and vitamin D(3) supplementation on serum intact parathyroid hormone in moderate CKD. Am J Kidney Dis 2009; 53: 408-416.
  375. Zisman AL, Hristova M, Ho LT et al. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol 2007; 27: 36-43.
  376. Coburn JW, Maung HM, Elangovan L et al. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis 2004; 43: 877-890.
  377. Coyne D, Acharya M, Qiu P et al. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis 2006; 47: 263-276.
  378. Birkenhager-Frenkel DH, Pols HA, Zeelenberg J et al. Effects of 24R,25-dihydroxyvitamin D3 in combination with 1 alpha-hydroxyvitamin D3 in predialysis renal insufficiency: biochemistry and histomorphometry of cancellous bone. J Bone Miner Res 1995; 10: 197-204.
  379. Chonchol M, Locatelli F, Abboud HE et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. Am J Kidney Dis 2009; 53: 197-207.
  380. Stevens LA, Djurdjev O, Cardew S et al. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 2004; 15: 770-779.
  381. Strippoli GF, Tong A, Palmer SC et al. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. Cochrane Database Syst Rev 2006: CD006254.
  382. Teng M, Wolf M, Ofsthun MN et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115-1125.
  383. Tentori F, Hunt WC, Stidley CA et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006; 70: 1858-1865.
  384. Teng M, Wolf M, Lowrie E et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-456.
  385. Tentori F, Albert JM, Young EW et al. The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant 2009; 24: 963-972.
  386. Cunningham J, Danese M, Olson K et al. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005; 68: 1793-1800.
  387. Block GA, Martin KJ, de Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350: 1516-1525.
  388. Lindberg JS, Culleton B, Wong G et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 2005; 16: 800-807.
  389. Malluche HH, Monier-Faugere MC, Wang G et al. An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clin Nephrol 2008; 69: 269-278.
  390. Jean G, Charra B, Chazot C. Vitamin D deficiency and associated factors in hemodialysis patients. J Ren Nutr 2008; 18: 395-399.
  391. Hayashi M, Tsuchiya Y, Itaya Y et al. Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicentre trial. Nephrol Dial Transplant 2004; 19: 2067-2073.
  392. Sprague SM, Llach F, Amdahl M et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003; 63: 1483-1490.
  393. Slatopolsky E, Finch J, Brown A. New vitamin D analogs. Kidney Int 2003; 63(Suppl 85): S83-87.
  394. Liou HH, Chiang SS, Huang TP et al. Comparative effect of oral or intravenous calcitriol on secondary hyperparathyroidism in chronic hemodialysis patients. Miner Electrolyte Metab 1994; 20: 97-102.
  395. Moe SM, Chertow GM, Coburn JW et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 2005; 67: 760-771.
  396. Fishbane S, Shapiro WB, Corry DB et al. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Clin J Am Soc Nephrol 2008; 3: 1718-1725.
  397. Greenbaum LA, Grenda R, Qiu P et al. Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis. Pediatr Nephrol 2005; 20: 622-630.
  398. Kuizon BD, Salusky IB. Intermittent calcitriol therapy and growth in children with chronic renal failure. Miner Electrolyte Metab 1998; 24: 290-295.
  399. Schmitt CP, Ardissino G, Testa S et al. Growth in children with chronic renal failure on intermittent versus daily calcitriol. Pediatr Nephrol 2003; 18: 440-444.
  400. Greenbaum LA, Benador N, Goldstein SL et al. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis. Am J Kidney Dis 2007; 49: 814-823.
  401. Jofre R, Lopez Gomez JM, Menarguez J et al. Parathyroidectomy: whom and when? Kidney Int 2003; 63(Suppl 85): S97-100.
  402. Neonakis E, Wheeler MH, Krishnan H et al. Results of surgical treatment of renal hyperparathyroidism. Arch Surg 1995; 130: 643-648.
  403. Gasparri G, Camandona M, Abbona GC et al. Secondary and tertiary hyperparathyroidism: causes of recurrent disease after 446 parathyroidectomies. Ann Sur 2001; 233: 65-69.
  404. Gagne ER, Urena P, Leite-Silva S et al. Short- and long-term efficacy of total parathyroidectomy with immediate autografting compared with subtotal parathyroidectomy in hemodialysis patients. J Am Soc Nephrol 1992; 3: 1008-1017.
  405. Kestenbaum B, Andress DL, Schwartz SM et al. Survival following parathyroidectomy among United States dialysis patients. Kidney Int 2004; 66: 2010-2016.
  406. Trombetti A, Stoermann C, Robert JH et al. Survival after parathyroidectomy in patients with end-stage renal disease and severe hyperparathyroidism. World J Sur 2007; 31: 1014-1021.
  407. Melton III LJ, Cummings SR. Heterogeneity of age-related fractures: implications for epidemiology. Bone Miner 1987; 2: 321-331.
  408. Keaveny TM, Bouxsein ML. Theoretical implications of the biomechanical fracture threshold. J Bone Miner Res 2008; 23: 1541-7.
  409. Chesnut C, Majumdar S, Gardner J et al. Assessment of bone quality, quantity, and turnover with multiple methodologies at multiple skeletal sites. Adv Exp Med Biol 2001; 496: 95-97.
  410. Hruska KA, Saab G, Mathew S et al. Renal osteodystrophy, phosphate homeostasis, and vascular calcification. Semin Dial 2007; 20: 309-315.
  411. Ballanti P, Wedard BM, Bonucci E. Frequency of adynamic bone disease and aluminum storage in Italian uraemic patients--retrospective analysis of 1429 iliac crest biopsies. Nephrol Dial Transplant 1996; 11: 663-667.
  412. Anderson GL, Limacher M, Assaf AR et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701-1712.
  413. Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
  414. Manson JE, Allison MA, Rossouw JE et al. Estrogen therapy and coronary-artery calcification. N Engl J Med 2007; 356: 2591-2602.
  415. Guevara A, Vidt D, Hallberg MC et al. Serum gonadotropin and testosterone levels in uremic males undergoing intermittent dialysis. Metabolism 1969; 18: 1062-1066.
  416. Solomon DH, Morris C, Cheng H et al. Medication use patterns for osteoporosis: an assessment of guidelines, treatment rates, and quality improvement interventions. Mayo Clin Proc 2005; 80: 194-202.
  417. Schousboe JT, Nyman JA, Kane RL et al. Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med 2005; 142: 734-741.
  418. MacLean C, Newberry S, Maglione M et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008; 148: 197-213.
  419. Wehrli FW, Ladinsky GA, Jones C et al. In vivo magnetic resonance detects rapid remodeling changes in the topology of the trabecular bone network after menopause and the protective effect of estradiol. J Bone Miner Res 2008; 23: 730-740.
  420. Borah B, Dufresne TE, Ritman EL et al. Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography. Bone 2006; 39: 345-352.
  421. Boivin GY, Chavassieux PM, Santora AC et al. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 2000; 27: 687-694.
  422. Currey JD. The design of mineralised hard tissues for their mechanical functions. J Exp Biol 1999; 202: 3285-3294.
  423. Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996; 18: 75-85.
  424. Tanko LB, Qin G, Alexandersen P et al. Effective doses of ibandronate do not influence the 3-year progression of aortic calcification in elderly osteoporotic women. Osteoporos Int 2004; 10: 10.
  425. Hill JA, Goldin JG, Gjertson D et al. Progression of coronary artery calcification in patients taking alendronate for osteoporosis. Acad Radiol 2002; 9: 1148-1152.
  426. Nitta K, Akiba T, Suzuki K et al. Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. Am J Kidney Dis 2004; 44: 680-688.
  427. Whitson HE, Lobaugh B, Lyles KW. Severe hypocalcemia following bisphosphonate treatment in a patient with Paget's disease of bone. Bone 2006; 39: 954-958.
  428. Maalouf NM, Heller HJ, Odvina CV et al. Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature. Endocr Pract 2006; 12: 48-53.
  429. Goh SK, Yang KY, Koh JS et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 2007; 89: 349-353.
  430. Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008; 358: 1304-1306.
  431. Black DM, Schwartz AV, Ensrud KE et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006; 296: 2927-2938.
  432. Jiang Y, Zhao JJ, Mitlak BH et al. Recombinant human parathyroid hormone (1-34) teriparatide improves both cortical and cancellous bone structure. J Bone Miner Res 2003; 18: 1932-1941.
  433. Arlot M, Meunier PJ, Boivin G et al. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res 2005; 20: 1244-1253.
  434. Black DM, Greenspan SL, Ensrud KE et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003; 349: 1207-1215.
  435. Finkelstein JS, Hayes A, Hunzelman JL et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003; 349: 1216-1226.
  436. Reeve J, Arlot ME, Bradbeer JN et al. Human parathyroid peptide treatment of vertebral osteoporosis. Osteoporos Int 1993; 3(Suppl 1): 199-203.
  437. Burr DB, Hirano T, Turner CH et al. Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res 2001; 16: 157-165.
  438. Ettinger B, Black DM, Mitlak BH et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999; 282: 637-645.
  439. Barrett-Connor E, Mosca L, Collins P et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006; 355: 125-137.
  440. Vogel VG, Costantino JP, Wickerham DL et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006; 295: 2727-2741.
  441. Ishani A, Blackwell T, Jamal SA et al. The effect of raloxifene treatment in postmenopausal women with CKD. J Am Soc Nephrol 2008; 19:1430-1438.
  442. Lu KC, Yeung LK, Lin SH et al. Acute effect of pamidronate on PTH secretion in postmenopausal hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 2003; 42: 1221-1227.
  443. Amerling R, Harbord N, Winchester JF et al. Bisphosphonate use in chronic kidney disease associated with adynamic bone disease. Abstract from the ISN Nexus Symposium on the Bone and the Kidney, 12-15 October 2006, Copenhagen, Denmark. International Society of Nephrology (ISN): Brussels, Belgium, 2006, p 33.
  444. Hernandez E, Valera R, Alonzo E et al. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney Int 2003; 63: 2269-2274.
  445. Postlethwaite RJ, Eminson DM, Reynolds JM et al. Growth in renal failure: a longitudinal study of emotional and behavioural changes during trials of growth hormone treatment. Arch Dis Child 1998; 78: 222-229.
  446. Sprague SM, Belozeroff V, Danese MD et al. Abnormal bone and mineral metabolism in kidney transplant patients--a review. Am J Nephrol 2008; 28: 246-53.
  447. Julian BA, Laskow DA, Dubovsky J et al. Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med 1991; 325: 544-550.
  448. Weisinger JR, Carlini RG, Rojas E et al. Bone disease after renal transplantation. Clin J Am Soc Nephrol 2006; 1: 1300-1313.
  449. Monier-Faugere MC, Mawad H, Qi Q et al. High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation. J Am Soc Nephrol 2000; 11: 1093-1099.
  450. Hernandez D, Rufino M, Bartolomei S et al. Clinical impact of preexisting vascular calcifications on mortality after renal transplantation. Kidney Int 2005; 67: 2015-2020.
  451. Moe SM, O'Neill KD, Reslerova M et al. Natural history of vascular calcification in dialysis and transplant patients. Nephrol Dial Transplant 2004; 19: 2387-2393.
  452. Egbuna OI, Taylor JG, Bushinsky DA et al. Elevated calcium phosphate product after renal transplantation is a risk factor for graft failure. Clin Transplant 2007; 21: 558-566.
  453. Stavroulopoulos A, Cassidy MJ, Porter CJ et al. Vitamin D status in renal transplant recipients. Am J Transplant 2007; 7: 2546-2552.
  454. Ghanekar H, Welch BJ, Moe OW et al. Post-renal transplantation hypophosphatemia: a review and novel insights. Curr Opin Nephrol Hypertens 2006; 15: 97-104.
  455. Yakupoglu HY, Corsenca A, Wahl P et al. Posttransplant acidosis and associated disorders of mineral metabolism in patients with a renal graft. Transplantation 2007; 84: 1151-1157.
  456. Schaeffner ES, Fodinger M, Kramar R et al. Prognostic associations of serum calcium, phosphate and calcium phosphate concentration product with outcomes in kidney transplant recipients. Transpl Int 2007; 20: 247-255.
  457. Torres A, Rodriguez AP, Concepcion MT et al. Parathyroid function in long-term renal transplant patients: importance of pre-transplant PTH concentrations. Nephrol Dial Transplant 1998; 13(Suppl 3): 94-97.
  458. Schmid T, Muller P, Spelsberg F. Parathyroidectomy after renal transplantation: a retrospective analysis of long-term outcome. Nephrol Dial Transplant 1997; 12: 2393-2396.
  459. Heaf J, Tvedegaard E, Kanstrup IL et al. Hyperparathyroidism and long-term bone loss after renal transplantation. Clin Transplant 2003; 17: 268-274.
  460. Dumoulin G, Hory B, Nguyen NU et al. No trend toward a spontaneous improvement of hyperparathyroidism and high bone turnover in normocalcemic long-term renal transplant recipients. Am J Kidney Dis 1997; 29: 746-753.
  461. 461. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266-281.
  462. Cannell JJ, Hollis BW, Zasloff M et al. Diagnosis and treatment of vitamin D deficiency. Expert Opin Pharmacother 2008; 9: 107-118.
  463. Reichrath J, Nurnberg B. Solar UV-radiation, vitamin D and skin cancer surveillance in organ transplant recipients (OTRs). Adv Exp Med Biol 2008; 624: 203-214.
  464. Akaberi S, Simonsen O, Lindergard B et al. Can DXA predict fractures in renal transplant patients? Am J Transplant 2008; 8: 2647-2651.
  465. Amin S, LaValley MP, Simms RW et al. The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach. Arthritis Rheum 1999; 42: 1740-1751.
  466. De Sevaux RG, Hoitsma AJ, Corstens FH et al. Treatment with vitamin D and calcium reduces bone loss after renal transplantation: a randomized study. J Am Soc Nephrol 2002; 13: 1608-1614.
  467. Torres A, Garcia S, Gomez A et al. Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation. Kidney Int 2004; 65: 705-712.
  468. Josephson MA, Schumm LP, Chiu MY et al. Calcium and calcitriol prophylaxis attenuates posttransplant bone loss. Transplantation 2004; 78: 1233-1236.
  469. Coco M, Glicklich D, Faugere MC et al. Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol 2003; 14: 2669-2676.
  470. Cueto-Manzano AM, Konel S, Freemont AJ et al. Effect of 1,25-dihydroxyvitamin D3 and calcium carbonate on bone loss associated with long-term renal transplantation. Am J Kidney Dis 2000; 35: 227-236.
  471. Jeffery JR, Leslie WD, Karpinski ME et al. Prevalence and treatment of decreased bone density in renal transplant recipients: a randomized prospective trial of calcitriol versus alendronate. Transplantation 2003; 76: 1498-1502.
  472. Conley E, Muth B, Samaniego M et al. Bisphosphonates and bone fractures in long-term kidney transplant recipients. Transplantation 2008; 86: 231-237.
  473. El-Husseini AA, El-Agroudy AE, El-Sayed MF et al. Treatment of osteopenia and osteoporosis in renal transplant children and adolescents. Pediatr Transplant 2004; 8: 357-361.
  474. El-Husseini AA, El-Agroudy AE, El-Sayed M et al. A prospective randomized study for the treatment of bone loss with vitamin d during kidney transplantation in children and adolescents. Am J Transplant 2004; 4: 2052-2057.
  475. Cunningham J, Sprague SM, Cannata-Andia J et al. Osteoporosis in chronic kidney disease. Am J Kidney Dis 2004; 43: 566-571.
  476. Miller PD, Schwartz EN, Chen P et al. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int 2007; 18: 59-68.
  477. Wissing KM, Broeders N, Moreno-Reyes R et al. A controlled study of vitamin D3 to prevent bone loss in renal-transplant patients receiving low doses of steroids. Transplantation 2005; 79: 108-115.
MAP
Home | Clinical Practice Guidlines | Meeting & Events | Initiatives | Publications | Resources

© Kidney disease: Improving Global Outcomes (KDIGO)
30 East 33rd Street, Suite 900 | New York, New York 10016-5337 USA,1 (212) 889-3427